度伐利尤单抗联合或不联合替西木单抗加化疗治疗HRR未突变铂耐药卵巢癌(KGOG 3045):一项II期伞式试验
KGOG 3045是一项开放标签、研究者发起的II期伞式试验,纳入58例无HRR基因突变且既往接受≥2线治疗的铂耐药复发性卵巢癌患者,按PD-L1表达分配至A组(度伐利尤单抗+化疗)、B组(度伐利尤单抗+替西木单抗75mg+化疗)、C组(度伐利尤单抗+替西木单抗300mg+化疗)和D组(度伐利尤单抗+化疗),客观缓解率分别为20.0%、33.3%、29.4%和22.2%。多因素分析显示在度伐利尤单抗+化疗基础上加用替西木单抗改善无进展生存(校正HR 0.435;95%CI 0.229-0.824;P=0.011)。
要点
- 铂耐药复发性卵巢癌无HRR突变患者中,双免疫联合化疗显示可接受的缓解率和耐受的安全性。
- 在度伐利尤单抗+化疗基础上加用替西木单抗改善无进展生存(校正HR 0.435;95%CI 0.229-0.824;P=0.011)。
- 对化学免疫治疗有利缓解与MUC16突变(P=0.0214)、高EPCAM表达(P=0.020)、高基质重塑基因特征评分(P=0.017)和低FOXP3表达(P=0.047)相关。
核心结论
- 在无HRR基因突变的铂耐药复发性卵巢癌中,双免疫联合化疗显示可接受的缓解率和耐受的安全性,值得继续临床研究。
研究设计与样本
- KGOG 3045是一项开放标签、研究者发起的II期伞式试验,纳入58例无HRR基因突变且既往接受≥2线治疗的铂耐药复发性卵巢癌患者。
- PD-L1高表达(TPS≥25%)患者分配至A组(度伐利尤单抗+化疗),PD-L1低表达患者分配至B组(度伐利尤单抗+替西木单抗75mg+化疗)。
- B组招募完成后,患者序贯分配至C组(度伐利尤单抗+替西木单抗300mg+化疗)和D组(度伐利尤单抗+化疗)。
- A、B、C、D组分别纳入5、18、17和18例患者。
主要发现
- A、B、C、D组客观缓解率分别为20.0%、33.3%、29.4%和22.2%。
- A、B、C、D组3-4级治疗相关不良事件发生率分别为20.0%、66.7%、47.1%和66.7%,但均得到有效管理。
- 多因素分析显示在度伐利尤单抗+化疗基础上加用替西木单抗改善无进展生存(校正HR 0.435;95%CI 0.229-0.824;P=0.011)。
- 对化学免疫治疗有利缓解与MUC16突变(P=0.0214)、高EPCAM表达(P=0.020)、高基质重塑基因特征评分(P=0.017)和低FOXP3表达(P=0.047)相关。
- 对度伐利尤单抗+替西木单抗+化疗有利缓解的患者EPCAM表达水平(P=0.008)和基质重塑基因特征评分(P=0.031)显著高于度伐利尤单抗+化疗患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We investigated the efficacy and safety of durvalumab (D) with or without tremelimumab (T) in addition to single-agent chemotherapy (CT) in patients with platinum-resistant recurrent ovarian cancer (PROC) lacking homologous recombination repair (HRR) gene mutations. PATIENTS AND METHODS: KGOG 3045 was an open-label, investigator-initiated phase II umbrella trial. Patients with PROC without HRR gene mutations who had received ≥2 prior lines of therapy were enrolled. Patients with high PD-L1 expression (TPS ≥25%) were assigned to arm A (D + CT), whereas those with low PD-L1 expression were assigned to arm B (D + T75 + CT). After completing arm B recruitment, patients were sequentially assigned to arms C (D + T300 + CT) and D (D + CT). RESULTS: Overall, 58 patients were enrolled (5, 18, 17, and 18 patients in arms A, B, C, and D, respectively). The objective response rates were 20.0, 33.3, 29.4, and 22.2%, respectively. Grade 3-4 treatment-related adverse events were observed in 20.0, 66.7, 47.1, and 66.7 of patients, respectively, but were effectively managed. Multivariable analysis demonstrated that adding T to D + CT improved progression-free survival (adjusted HR, 0.435; 95% CI, 0.229-0.824; P = 0.011). Favorable response to chemoimmunotherapy was associated with MUC16 mutation (P = 0.0214), high EPCAM expression (P = 0.020), high matrix remodeling gene signature score (P = 0.017), and low FOXP3 expression (P = 0.047). Patients showing favorable responses to D + T + CT exhibited significantly higher EPCAM expression levels (P = 0.008) and matrix remodeling gene signature scores (P = 0.031) than those receiving D + CT. CONCLUSIONS: Dual immunotherapy with chemotherapy showed acceptable response rates and tolerable safety in HRR non-mutated PROC, warranting continued clinical investigation.
引用
- Kim SI, Joung JG, Kim YN, et al. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial. Gynecol Oncol. 2024. PMID: 38246047. doi:10.1016/j.ygyno.2023.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。